Artiva Biotherapeutics is preparing to release pivotal data from its unmodified, preserved natural killer (NK) cell therapy for autoimmune indications, with topline results expected within the next quarter. This product candidate leverages off-the-shelf NK cells engineered to persist without genetic modification, aiming to circumvent manufacturing delays and safety concerns characteristic of CAR T-cell approaches. Early signals of anti-tumor activity in a Phase 1 study of B-cell lymphoma showed objective responses in 3 of 12 evaluable patients, supporting the company’s strategy to extend its platform into autoimmune diseases such as lupus and rheumatoid arthritis.

Six research firms covering Artiva have produced a consensus recommendation of “Moderate Buy,” with an average 12-month price objective of $19.00. Among these, one analyst retains a sell view, four maintain buy ratings and one upgraded to strong buy. Jefferies Financial Group initiated a strong-buy stance in mid-November, while HC Wainwright lifted its target from $12 to $15 in early November. Wedbush increased its outlook to outperform with a $23 objective in October, reflecting growing confidence in Artiva’s manufacturing scalability and clinical milestones.

CEO Fred Aslan sold 25,500 shares on October 17 at an average price of $6.00, generating proceeds of $153,000. Post-transaction, Aslan holds 356,721 shares, representing a 6.7% reduction in his stake. Over the past 90 days, insiders have disposed of 35,062 shares valued at $193,670. Despite the sales, insiders still command 21.4% of the company’s outstanding stock, indicating continued alignment with long-term platform development and capital-efficient expansion plans.

Several hedge funds and asset managers have initiated or expanded exposure to Artiva. Bank of America Corp. DE increased its stake by 225.8% during the third quarter, buying 11,190 additional shares to reach 16,145 shares in total. Ground Swell Capital and Prelude Capital Management established new positions worth approximately $38,000 and $41,000, respectively, while Y Intercept Hong Kong and Bridgeway Capital each allocated around $48,000–$53,000 in the second quarter. These moves suggest growing institutional interest in Artiva’s allogeneic NK cell platform ahead of upcoming clinical catalysts.